The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Daratumumab, bortezomib & dexamethasone at first relapse: real-world study in patients with myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, describes the results of a real-world multicenter study which evaluated the safety and efficacy of daratumumab, bortezomib and dexamethasone (DVd) at first relapse in patients with multiple myeloma. Dr Popat highlights the CASTOR trial (NCT02136134), which led to the approval of this combination, and explains that the results of this real-world study reflect the findings of the CASTOR study, particularly in progression-free survival (PFS) and time to next treatment (TTNT). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
